CVRx Launches Barostim NEO2 Implantable Pulse Generator

CVRx Inc. has debuted its new Barostim NEO2 IPG.

“The new Barostim NEO2 is another leap forward in improving the patient and provider experience with Barostim Therapy,” CVRx President and CEO Nadim Yared said. “These upgrades enable improved longevity using a smaller footprint and allow physicians to implant the device more easily than ever before.”
 
The second-generation device reduces the size of the IPG by 10% and extends battery life by 20%, reducing the frequency of device replacements for patients and their providers. The Barostim NEO2 also offers a streamlined design with a single lead port (compared with two in the prior generation device) to further simplify the implant procedure. All Barostim Programmer models are compatible with the new IPG model.
 
“The new Barostim NEO2 offers the same clinically proven Barostim Therapy, but with a more convenient design for my patients that is smaller and lasts longer,” said Dr. Michael Hoosien, electrophysiologist at Piedmont Atlanta. “We are excited to use this next generation system to further expand our Barostim program.” 
 
CVRx develops and commercializes the Barostim System, the first medical technology approved by the U.S. Food and Drug Administration (FDA) that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received FDA Breakthrough Device designation and also received the CE Mark for heart failure and resistant hypertension.